CoChat
Sign Up
Cited by 196

The DOI matches its Crossref record.

Active targeting drug delivery nanocarriers: Ligands

Salahpour Anarjan, Fatemeh·2019·Nano-Structures & Nano-Objects
DOI 10.1016/j.nanoso.2019.100370
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/j.nanoso.2019.100370

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 55

  1. Xiong, 2011, Active targeting behaviors of biotinylated Pluronic/poly (lactic acid) nanoparticles in vitro through three-step biotin-avidin interaction, J. Biomater. Sci. Polym. Ed., 22, 1607, 10.1163/092050610X519444 · DOI
  2. Galvin, 2012, Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications, Cell. Mol. Life Sci., 69, 389, 10.1007/s00018-011-0856-6 · DOI
  3. Hirsjarvi, 2011, Passive and active tumour targeting with nanocarriers, Curr. Drug Discov. Technol., 8, 188, 10.2174/157016311796798991 · DOI
  4. Farokhzad, 2009, Impact of nanotechnology on drug delivery, ACS Nano, 3, 16, 10.1021/nn900002m · DOI
  5. Wang, 2016, Active targeting liposomes: Promising approach for tumor-targeted therapy, J. Bioequiv. Availab., 08
  6. Mirshafiee, 2013, Protein corona significantly reduces active targeting yield, Chem. Commun. (Camb), 49, 2557, 10.1039/c3cc37307j · DOI
  7. Byrne, 2008, Active targeting schemes for nanoparticle systems in cancer therapeutics, Adv. Drug Deliv. Rev., 60, 1615, 10.1016/j.addr.2008.08.005 · DOI
  8. Chapman, 2002, PEGylated antibodies and antibody fragments for improved therapy: a review, Adv. Drug Deliv. Rev., 54, 531, 10.1016/S0169-409X(02)00026-1 · DOI
  9. Yu, 2015, Clearance pathways and tumor targeting of imaging nanoparticles, ACS Nano, 9, 6655, 10.1021/acsnano.5b01320 · DOI
  10. Xu, 2013, Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances, Adv. Drug Deliv. Rev., 65, 121, 10.1016/j.addr.2012.09.041 · DOI
  11. Huang, 2013, Tumor targeting and microenvironment-responsive nanoparticles for gene delivery, Biomaterials, 34, 5294, 10.1016/j.biomaterials.2013.03.043 · DOI
  12. Sutradhar, 2014, Nanotechnology in cancer drug delivery and selective targeting, ISRN Nanotechnol., 2014, 1, 10.1155/2014/939378 · DOI · Paper page
  13. Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol., 2, 751, 10.1038/nnano.2007.387 · DOI · Paper page
  14. Watanabe, 2018, Stability and drug release studies of an antimycotic nanomedicine using HPLC, dynamic light scattering and atomic force microscopy, J. Pharm. Biomed. Anal., 148, 149, 10.1016/j.jpba.2017.09.030 · DOI
  15. Iqbal, 2014, Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications, Mol. Biol. Int., 2014, 10.1155/2014/852748 · DOI
  16. Zwicke, 2012, Utilizing the folate receptor for active targeting of cancer nanotherapeutics, Nano Rev., 3, 10.3402/nano.v3i0.18496 · DOI · Paper page
  17. Shreya, 2019, Active targeting of drugs and bioactive molecules via oral administration by ligand-conjugated lipidic nanocarriers: Recent advances, AAPS PharmSciTech., 20, 15, 10.1208/s12249-018-1262-2 · DOI
  18. Ganguly, 2013, Integrins and metastasis, Cell Adh. Migr., 7, 251, 10.4161/cam.23840 · DOI
  19. Milenic, 2004, Antibody-targeted radiation cancer therapy, Nat. Rev. Drug Discov., 3, 488, 10.1038/nrd1413 · DOI · Paper page
  20. Chen, 2013, Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer, Int. J. Nanomedicine, 8, 3781
  21. Sultana, 2013, Nanoparticles-mediated drug delivery approaches for cancer targeting: a review, J. Drug Target., 21, 107, 10.3109/1061186X.2012.712130 · DOI
  22. Zhai, 2015, Epidermal growth factor receptor-targeted lipid nanoparticles retain self-assembled nanostructures and provide high specificity, Nanoscale, 7, 2905, 10.1039/C4NR05200E · DOI
  23. Liang, 2015, Circulating VEGF as a biomarker for diagnosis of ovarian cancer: a systematic review and a meta-analysis, Onco. Targets Ther., 8, 1075
  24. Ku, 2014, Tumor-targeting multifunctional nanoparticles for sirna delivery: recent advances in cancer therapy, Adv. Healthc. Mater., 3, 1182, 10.1002/adhm.201300607 · DOI
  25. Steinhauser, 2006, Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells, Biomaterials, 27, 4975, 10.1016/j.biomaterials.2006.05.016 · DOI
  26. Corsi, 2011, HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice, ACS Nano, 5, 6383, 10.1021/nn201570n · DOI
  27. Bacac, 2016, A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors, Clin. Cancer Res., 22, 3286, 10.1158/1078-0432.CCR-15-1696 · DOI
  28. Gu, 2018, Aptamer-conjugated multi-walled carbon nanotubes as a new targeted ultrasound contrast agent for the diagnosis of prostate cancer, J. Nanoparticle Res. Interdiscip. Forum Nanoscale Sci. Technol., 20, 303
  29. Liu, 2009, Aptamer-nanoparticle strip biosensor for sensitive detection of cancer cells, Anal. Chem., 81, 10013, 10.1021/ac901889s · DOI
  30. Wu, 2015, Aptamers: active targeting ligands for cancer diagnosis and therapy, Theranostics, 5, 322, 10.7150/thno.10257 · DOI
  31. Smith, 2007, Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells, Anal. Chem., 79, 3075, 10.1021/ac062151b · DOI
  32. Cheng, 2011, Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides, Biomaterials, 32, 6194, 10.1016/j.biomaterials.2011.04.053 · DOI
  33. Patil, 2016, Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity, J. Control Release, 225, 87, 10.1016/j.jconrel.2016.01.039 · DOI
  34. Paranjpe, 2004, Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation, J. Control. Release, 100, 275, 10.1016/j.jconrel.2004.08.030 · DOI
  35. You, 2008, Folate-conjugated polymer micelles for active targeting to cancer cells: preparation, in vitro evaluation of targeting ability and cytotoxicity, Nanotechnology, 19, 45102, 10.1088/0957-4484/19/04/045102 · DOI
  36. Li, 2009, In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles, Cancer Lett., 274, 319, 10.1016/j.canlet.2008.09.024 · DOI
  37. Hong, 2009, Efficient tumor targeting of hydroxycamptothecin loaded pegylated niosomes modified with transferrin, J. Control. Release, 133, 96, 10.1016/j.jconrel.2008.09.005 · DOI
  38. Dufes, 2000, Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting, Pharm. Res., 17, 1250, 10.1023/A:1026422915326 · DOI
  39. Davis, 2009, The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic, Mol. Pharm., 6, 659, 10.1021/mp900015y · DOI
  40. Galaway, 2013, MS2 viruslike particles: A robust, semisynthetic targeted drug delivery platform, Mol. Pharm., 10, 59, 10.1021/mp3003368 · DOI
  41. Miyata, 2011, Computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy, Neurosurgery, 68, 1380, 10.1227/NEU.0b013e31820b52aa · DOI
  42. Maggi, 2018, Gold nanoparticles functionalized with RGD-semipeptides: A simple yet highly effective targeting system for αvβ3 integrins, Chem. Eur. J., 24, 12093, 10.1002/chem.201801823 · DOI
  43. Schaffner, 2013, Integrin α5β1, the fibronectin receptor, as a pertinent therapeutic target in solid tumors, Cancers (Basel), 5, 27, 10.3390/cancers5010027 · DOI
  44. Viale, 2018, Cyclodextrin polymers decorated with RGD peptide as delivery systems for targeted anti-cancer chemotherapy, Invest. New Drugs, 1
  45. Mygind, 2018, Loss of ADAM9 expression impairs β1 integrin endocytosis, focal adhesion formation and cancer cell migration, J. Cell Sci., 131, jcs205393, 10.1242/jcs.205393 · DOI
  46. Weis, 2011, αV integrins in angiogenesis and cancer, Cold Spring Harb. Perspect. Med., 1, 10.1101/cshperspect.a006478 · DOI
  47. Nieberler, 2017, Exploring the role of RGD-recognizing integrins in cancer, Cancers (Basel), 9, 10.3390/cancers9090116 · DOI
  48. Landeros-Martínez, 2018, Studying the chemical reactivity properties of the target tumor-environment tripeptides NGR (asparagine-glycine-arginine) and RGD (arginine-glycine-aspartic acid) in their interactions with tamoxifen through conceptual density functional theory, J. Mol. Model., 24, 336, 10.1007/s00894-018-3868-4 · DOI
  49. Ge, 2018, Screening of novel RGD peptides to modify nanoparticles for targeted cancer therapy, Biomater. Sci., 6, 125, 10.1039/C7BM00776K · DOI
  50. Kunjachan, 2014, Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines, Nano Lett., 14, 972, 10.1021/nl404391r · DOI
  51. Kalliokoski, 2013, Comparability of mixed IC50 data–a statistical analysis, PLoS One, 8, 10.1371/journal.pone.0061007 · DOI
  52. Yonenaga, 2012, RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment, J. Control. Release, 160, 177, 10.1016/j.jconrel.2011.10.004 · DOI
  53. Luo, 2017, Dual-targeted and ph-sensitive doxorubicin prodrug-microbubble complex with ultrasound for tumor treatment, Theranostics, 7, 452, 10.7150/thno.16677 · DOI
  54. Zhang, 2018, A multifunctional targeting probe with dual-mode imaging and photothermal therapy used in vivo, J. Nanobiotechnology, 16, 42, 10.1186/s12951-018-0367-9 · DOI
  55. Amin, 2013, Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with n-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas, Int. J. Pharm., 458, 324, 10.1016/j.ijpharm.2013.10.018 · DOI

Cited by

Sorted by citations

Metadata

Authors
Salahpour Anarjan, F.
Venue
Nano-Structures & Nano-Objects
Publisher
Elsevier BV
Published
2019-07
Volume
19
Pages
100370
ISSN
2352-507X
DOI
10.1016/j.nanoso.2019.100370
Cited by
196
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review